Mayo Clinic reports that this could include itching and trouble swallowing
Human studies have demonstrated good outcomes for weight reduction in people with ( 2.62 kg) and without ( 5.09 kg) T2D over 4 weeks compared with placebo [50]
Eligibility criteria: First, we identified patients meeting claims-based criteria for T2D between 01/01/2011 and 12/31/2019, using International Classification of Disease, Ninth/Tenth Revision, Clinical Modification (ICD-9/10-CM) diagnosis codes occurred at the primary or secondary position from inpatient, outpatient or carrier claims (Supplement Table 2)
Patients were randomized to receive final doses of 30 mg, 50 mg, or 70 mg of VYVANSE or placebo once daily in the morning for a total of four weeks of treatment
Food reduces that number even further, potentially cutting absorption by more than 50%
The glucagon activation primarily drives fat burning rather than glucose release in this context